Full Text View
Tabular View
Study Results
Related Studies
An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus
This study has been completed.
Study NCT00135330   Information provided by Amylin Pharmaceuticals, Inc.
First Received: August 24, 2005   Last Updated: July 21, 2009   History of Changes
Study Type: Interventional
Study Design: Randomized, Open Label, Active Control, Parallel Assignment
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: exenatide
Drug: rosiglitazone

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Enrollment occurred between 18 October 2005 and 14 March 2008.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Exenatide Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.
Exenatide Plus Rosiglitazone Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.
Rosiglitazone Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.

Participant Flow:   Overall Study
  Exenatide Exenatide Plus Rosiglitazone Rosiglitazone
STARTED   45     47     45  
COMPLETED   33     34     34  
NOT COMPLETED   12     13     11  
      Adverse Event               2                 5                 1  
      Lost to Follow-up               0                 2                 3  
      Physician Decision               1                 1                 0  
      Protocol Violation               4                 3                 3  
      Patient Decision               5                 1                 4  
      Sponsor Decision               0                 1                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Exenatide Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.
Exenatide Plus Rosiglitazone Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.
Rosiglitazone Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.

Baseline Measures
  Exenatide Exenatide Plus Rosiglitazone Rosiglitazone Total
Number of Participants  
[units: participants]
45 47 45 137
Age  
[units: participants]
       
<=18 years 0 0 0 0
Between 18 and 65 years 36 37 36 109
>=65 years 9 10 9 28
Age  
[units: years]
Mean ± Standard Deviation
56.99 ± 9.71 54.63 ± 9.91 55.54 ± 10.71 55.70 ± 10.09
Gender  
[units: participants]
       
Female 22 25 20 67
Male 23 22 25 70



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in ASIiAUC During a Hyperglycemic Clamp Test.   [ 20 weeks ]

2.  Secondary:   Change in AUC for Glucose During a Meal Challenge Test (MCT).   [ Week 20 ]

3.  Secondary:   Change in Insulin Sensitivity Index as Measured by M-value.   [ Week 20 ]

4.  Secondary:   Change in Insulin AUC in the First Stage From Baseline to Endpoint.   [ Week 20 ]

5.  Secondary:   Change in Insulin iAUC From Baseline to Endpoint.   [ Week 20 ]

6.  Secondary:   Ratio (Value at Endpoint Divided by Value at Baseline) of AUC for Insulin During a Meal Challenge Test (MCT).   [ Week 20 ]

7.  Secondary:   Change in AUC for C-peptide During a Meal Challenge Test (MCT).   [ Week 20 ]

8.  Secondary:   Change in Incremental for Postprandial Glucose During a Meal Challenge Test (MCT).   [ Week 20 ]

9.  Secondary:   Change in Incremental for Postprandial Insulin During Meal Challenge Test (MCT).   [ Week 20 ]

10.  Secondary:   Change in Incremental for Postprandial C-peptide During Meal Challenge Test (MCT).   [ Week 20 ]

11.  Secondary:   Change in HbA1c   [ Week 20 ]

12.  Secondary:   Change in Fasting Serum Glucose Concentration.   [ Week 20 ]

13.  Secondary:   Change in Fasting C-peptide   [ Week 20 ]

14.  Secondary:   Change in Fasting Insulin   [ Week 20 ]

15.  Secondary:   Change in Fasting Proinsulin   [ Week 20 ]

16.  Secondary:   Change in Body Weight   [ Week 20 ]

17.  Secondary:   Change in Fasting Total Cholesterol.   [ Week 20 ]

18.  Secondary:   Change in Fasting HDL Cholesterol   [ Week 20 ]

19.  Secondary:   Change in Fasting LDL Cholesterol   [ Week 20 ]

20.  Secondary:   Change in Fasting Triglycerides   [ Week 20 ]

21.  Secondary:   Change in Percent Body Fat During a Meal Challenge Test (MCT)   [ 20 weeks ]

22.  Secondary:   Change in Body Fat Mass During a Meal Challenge Test (MCT)   [ 20 weeks ]

23.  Secondary:   Change in Lean Body Mass During a Meal Challenge Test (MCT)   [ 20 weeks ]

24.  Secondary:   Change in Waist Circumference   [ 20 weeks ]

25.  Secondary:   Change in Hip Circumference   [ 20 weeks ]

26.  Secondary:   Change in Waist-to-hip Ratio   [ 20 weeks ]

27.  Secondary:   Incidence of Hypoglycemia Events   [ 20 weeks ]

28.  Secondary:   Hypoglycemia Rate Per 30 Days Per Patient   [ 20 weeks ]

29.  Secondary:   Pedal Edema Score   [ 20 weeks ]


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Show More Information